Literature DB >> 26189978

Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy.

Gretchen Kimmick1, Sara N Edmond2, Hayden B Bosworth3, Jeffrey Peppercorn4, Paul K Marcom4, Kimberly Blackwell4, Francis J Keefe2, Rebecca A Shelby2.   

Abstract

PURPOSE: To explore how symptoms and psychosocial factors are related to intentional and unintentional non-adherent medication taking behaviors.
METHODS: Included were postmenopausal women with hormone receptor positive, stage I-IIIA breast cancer, who had completed surgery, chemotherapy, and radiation, and were taking endocrine therapy. Self-administered, standardized measures were completed during a routine clinic visit: Brief Fatigue Inventory, Brief Pain Inventory, Menopause Specific Quality of Life Questionnaire, Functional Assessment of Cancer Therapy General and Neurotoxicity scales, and Self-Efficacy for Appropriate Medication Use Scale. Regression analyses were performed to determine the degree to which demographic, medical, symptom, and psychosocial variables, explain intentional, such as changing one's doses or stopping medication, and unintentional, such as forgetting to take one's medication, non-adherent behaviors.
RESULTS: Participants were 112 women: mean age 64 (SD = 9) years; 81% white; mean time from surgery 40 (SD = 28) months; 49% received chemotherapy (39% including a taxane); mean time on endocrine therapy, 35 (SD = 29.6) months; 82% taking an aromatase inhibitor. Intentional and unintentional non-adherent behaviors were described in 33.9% and 58.9% of participants, respectively. Multivariate analysis showed that higher self-efficacy for taking medication was associated with lower levels of unintentional (p = 0.002) and intentional (p = 0.004) non-adherent behaviors. The presence of symptoms (p = 0.03) and lower self-efficacy for physician communication (p = 0.009) were associated with higher levels of intentional non-adherent behaviors.
CONCLUSIONS: These results suggest that women who report greater symptoms, lower self-efficacy for communicating with their physician, and lower self-efficacy for taking their medication are more likely to engage in both intentional and unintentional non-adherent behaviors.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adherence; Breast cancer; Endocrine therapy; Self-efficacy

Mesh:

Substances:

Year:  2015        PMID: 26189978      PMCID: PMC4824055          DOI: 10.1016/j.breast.2015.06.010

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  60 in total

1.  Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: a TEAM study analysis.

Authors:  Willemien van de Water; Esther Bastiaannet; Elysée T M Hille; Elma M Meershoek-Klein Kranenbarg; Hein Putter; Caroline M Seynaeve; Robert Paridaens; Anton J M de Craen; Rudi G J Westendorp; Gerrit-Jan Liefers; Cornelis J H van de Velde
Journal:  Oncologist       Date:  2011-12-30

2.  Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness.

Authors:  R Horne; J Weinman
Journal:  J Psychosom Res       Date:  1999-12       Impact factor: 3.006

Review 3.  Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy.

Authors:  Peyman Hadji
Journal:  Crit Rev Oncol Hematol       Date:  2009-03-18       Impact factor: 6.312

4.  New medication adherence scale versus pharmacy fill rates in seniors with hypertension.

Authors:  Marie Krousel-Wood; Tareq Islam; Larry S Webber; Richard N Re; Donald E Morisky; Paul Muntner
Journal:  Am J Manag Care       Date:  2009-01       Impact factor: 2.229

Review 5.  Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer.

Authors:  Lorena Rocha Ayres; André de Oliveira Baldoni; Anna Paula de Sá Borges; Leonardo Régis Leira Pereira
Journal:  Int J Clin Pharm       Date:  2013-08-11

6.  Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication.

Authors:  Yihang Liu; Jennifer L Malin; Allison L Diamant; Amardeep Thind; Rose C Maly
Journal:  Breast Cancer Res Treat       Date:  2012-12-23       Impact factor: 4.872

7.  Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptor-positive invasive breast cancer nearly 4 years from diagnosis.

Authors:  Robin J Bell; Pamela Fradkin; Max Schwarz; Susan R Davis
Journal:  Menopause       Date:  2013-01       Impact factor: 2.953

8.  Prognostic importance of comorbidity in a hospital-based cancer registry.

Authors:  Jay F Piccirillo; Ryan M Tierney; Irene Costas; Lori Grove; Edward L Spitznagel
Journal:  JAMA       Date:  2004-05-26       Impact factor: 56.272

9.  Adherence to medication in bipolar disorder: a qualitative study exploring the role of patients' beliefs about the condition and its treatment.

Authors:  Jane Clatworthy; Richard Bowskill; Tim Rank; Rhian Parham; Rob Horne
Journal:  Bipolar Disord       Date:  2007-09       Impact factor: 6.744

10.  Interruption and non-adherence to long-term adjuvant hormone therapy is associated with adverse survival outcome of breast cancer women--an Asian population-based study.

Authors:  Kun-Pin Hsieh; Li-Chia Chen; Kwok-Leung Cheung; Chao-Sung Chang; Yi-Hsin Yang
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

View more
  26 in total

1.  Symptoms and QOL in breast cancer patients receiving hormone therapy in Japan.

Authors:  Yukiko Iioka; Takako Iwata; Hideko Yamauchi
Journal:  Breast Cancer       Date:  2019-07-11       Impact factor: 4.239

2.  Higher symptom burden is associated with lower function in women taking adjuvant endocrine therapy for breast cancer.

Authors:  Andrea Sitlinger; Rebecca A Shelby; Alyssa N Van Denburg; Heidi White; Sarah N Edmond; Paul K Marcom; Hayden B Bosworth; Francis J Keefe; Gretchen G Kimmick
Journal:  J Geriatr Oncol       Date:  2018-12-13       Impact factor: 3.599

3.  Use of a web-based app to improve breast cancer symptom management and adherence for aromatase inhibitors: a randomized controlled feasibility trial.

Authors:  Ilana Graetz; Caitlin N McKillop; Edward Stepanski; Gregory A Vidal; Janeane N Anderson; Lee S Schwartzberg
Journal:  J Cancer Surviv       Date:  2018-02-28       Impact factor: 4.442

4.  Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET).

Authors:  Rebecca A Shelby; Caroline S Dorfman; Hayden B Bosworth; Francis Keefe; Linda Sutton; Lynda Owen; Leonor Corsino; Alaattin Erkanli; Shelby D Reed; Sarah S Arthur; Tamara Somers; Nadine Barrett; Scott Huettel; Juan Marcos Gonzalez; Gretchen Kimmick
Journal:  Contemp Clin Trials       Date:  2018-11-22       Impact factor: 2.226

5.  Investigating Associations Between Health-Related Quality of Life and Endocrine Therapy Underuse in Women With Early-Stage Breast Cancer.

Authors:  Laura C Pinheiro; Stephanie B Wheeler; Katherine E Reeder-Hayes; Cleo A Samuel; Andrew F Olshan; Bryce B Reeve
Journal:  J Oncol Pract       Date:  2017-03-14       Impact factor: 3.840

6.  Provider perspectives on barriers and facilitators to adjuvant endocrine therapy-related symptom management.

Authors:  Cleo A Samuel; Kea Turner; Heidi A S Donovan; Ellen Beckjord; Alexandra Cardy; Mary Amanda Dew; G J van Londen
Journal:  Support Care Cancer       Date:  2017-07-06       Impact factor: 3.603

7.  Partner status moderates the relationships between sexual problems and self-efficacy for managing sexual problems and psychosocial quality-of-life for postmenopausal breast cancer survivors taking adjuvant endocrine therapy.

Authors:  Caroline S Dorfman; Sarah S Arthur; Gretchen G Kimmick; Kelly W Westbrook; Paul Kelly Marcom; Cheyenne Corbett; Sara N Edmond; Rebecca A Shelby
Journal:  Menopause       Date:  2019-08       Impact factor: 2.953

8.  Improving health engagement and lifestyle management for breast cancer survivors with diabetes.

Authors:  Rebecca A Shelby; Caroline S Dorfman; Sarah S Arthur; Hayden B Bosworth; Leonor Corsino; Linda Sutton; Lynda Owen; Alaattin Erkanli; Francis Keefe; Cheyenne Corbett; Gretchen Kimmick
Journal:  Contemp Clin Trials       Date:  2020-04-11       Impact factor: 2.226

9.  A systematic review of interventions to improve adherence to endocrine therapy.

Authors:  Sue P Heiney; Pearman D Parker; Tisha M Felder; Swann Arp Adams; Omonefe O Omofuma; Jennifer M Hulett
Journal:  Breast Cancer Res Treat       Date:  2018-11-01       Impact factor: 4.872

10.  Race and Patient-reported Symptoms in Adherence to Adjuvant Endocrine Therapy: A Report from the Women's Hormonal Initiation and Persistence Study.

Authors:  Vanessa B Sheppard; Arnethea L Sutton; Alejandra Hurtado-de-Mendoza; Jun He; Bassam Dahman; Megan C Edmonds; Mary Helen Hackney; Mahlet G Tadesse
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-01-29       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.